Regresar

Determinación de concordancia de expresividad de HER - 2 entre inmunohistoquimica e hibridizacion in situ fluorescente (FISH) y su relación con expresión de topoisomerasa A2 en carcinoma invasor de mama en el Hospital Carlos Andrade Marín. 2012-2013

Abstract:

Background: The clinical benefit of the determination of Her 2/neu amplification, in breast cancer patients, its well accepted; this protooncogen is amplificated in 20-30% of the breast tumors and this determination is important to asses those patients who are sensitive of an individualized therapy. Although the Inmunohistochemestry (IHC) is frequently used to evaluate the overexpression, the Fluorescence In situ Hybridization (FISH), is the gold standard and newly the expression of Topoisomerasa 2A has been involved in the pbkp_rediction of the clinical evolution and the success of chemotherapy specific antraciclinas in the breast cancer patients. Objetive: Evaluate the correspondence of Her2neu in FISH and in inmunohistochemical (IHC) and compare with the presence of Topoisomerase 2A. Design: Clinical non-controlled to assess diagnostic test. Methods: Pathology Service, Hospital Carlos Andrade Marín, Quito-2013. 2 blocks of tissue micro arrangements were prepared with 60 breast tumors. From each block, 3 histological plates were prepared, stained with Hematoxylin- Eosin, Her2 neu FISH and TOP 2A FISH. The correspondence between these different methodologies were evaluated by complex repeatability and Cohen’s Kappa index, the diagnosis of inmunohistochemical study to Her2 compared with the results of FISH were established by sensibility, specificity, pbkp_redictive values and authenticity reasons...